z-logo
Premium
Riluzole inhibits spontaneous Ca 2+ signaling in neuroendocrine cells by activation of K + channels and inhibition of Na + channels
Author(s) -
BeltranParrazal Luis,
Charles Andrew
Publication year - 2003
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705491
Subject(s) - riluzole , iberiotoxin , chemistry , patch clamp , endocrinology , medicine , pharmacology , biophysics , potassium channel , glutamate receptor , biology , biochemistry , receptor
The neuroprotective drug riluzole has multiple effects on cellular signaling. We found that riluzole rapidly and reversibly inhibited spontaneous Ca 2+ oscillations in both immortalized GnRH‐secreting hypothalamic neurons (GT1 cells) and in the prolactin and growth‐hormone‐secreting GH 3 cell line. At lower concentrations (100 n M –5 μ M ), riluzole reduced the amplitude and frequency of spontaneous Ca 2+ oscillations, whereas at higher concentrations it abolished spontaneous Ca 2+ signaling. Whole‐cell current clamp recordings in GH 3 cells revealed that riluzole decreased the action potential frequency, amplitude, and duration. Riluzole inhibited voltage‐gated Na + currents, increased iberiotoxin‐sensitive voltage‐gated K + currents, and had no effect on voltage‐gated Ca 2+ currents in GH 3 cells. Riluzole also inhibited voltage‐gated Na + currents and increased voltage‐gated K + channels in GT1 cells. The inhibitory effects of riluzole on Ca 2+ signaling were blocked by pretreatment with iberiotoxin in GH 3 cells, but only partially reduced by iberiotoxin in GT1 cells. These results indicate that riluzole inhibits Ca 2+ signaling primarily by activation of K + channels in GH 3 cells, and also by inhibition of Na + channels in GT1 cells. Riluzole's inhibition of spontaneous excitability and Ca 2+ signaling may be involved in its multiple effects on cellular function in the nervous system.British Journal of Pharmacology (2003) 140 , 881–888. doi: 10.1038/sj.bjp.0705491

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom